Research graph
References from The canine tumour micro-environment and advances in antitumour therapy in canine melanoma. Local targets link to admitted publications; unresolved targets remain external evidence.
Evaluation of tumor immunity after administration of conditionally replicative adenoviral vector in canine osteosarcoma patients
10.1016/j.heliyon.2021.e06210 · 2021 · External reference
Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas
10.1354/vp.44-6-823 · 2007 · External reference
Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma
10.1007/s00262-005-0025-6 · 2006 · External reference
NY‐ESO‐1 antigen: A promising frontier in cancer immunotherapy
10.1002/ctm2.70020 · 2024 · External reference
Predictors of mucosal melanoma survival in a population-based setting
10.1016/j.jaad.2018.09.054 · 2019 · External reference
Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity
10.1158/0008-5472.can-12-3366 · 2013 · External reference
Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours
10.1016/j.vetimm.2020.110142 · 2020 · External reference
Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients
10.4049/jimmunol.172.5.3289 · 2004 · External reference
A retrospective study of 101 dogs with oral melanoma treated with a weekly or biweekly 6 Gy × 6 radiotherapy protocol
10.1111/vco.12815 · 2022 · External reference
Prognosis of acral melanoma: A series of 281 patients
10.1245/s10434-013-3089-0 · 2013 · External reference
Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center
10.1016/j.vaccine.2005.08.027 · 2006 · External reference
Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial
2003 · External reference
Autologous hybrid cell fusion vaccine in a spontaneous intermediate model of breast carcinoma
10.4142/jvs.2019.20.e48 · 2019 · External reference
Efficacy of systemic adjuvant therapies administered to dogs after excision of oral malignant melanomas: 151 cases (2001–2012)
10.2460/javma.245.4.401 · 2014 · External reference
Tumor immune microenvironment and its clinicopathological and prognostic associations in canine splenic hemangiosarcoma
10.3390/ani14081224 · 2024 · External reference
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 · External reference
Design of a randomized, placebo-controlled study evaluating efficacy and safety of a cancer preventative vaccine in dogs
10.1016/j.vetimm.2023.110691 · 2024 · External reference
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
10.1038/s41586-019-1914-8 · 2020 · External reference
Clinical evaluation of HuDo-CSPG4 DNA electroporation as adjuvant treatment for canine oral malignant melanoma: Comparison of two vaccination protocols
10.1080/01652176.2025.2473717 · 2025 · External reference
Intratumoral FoxP3 expression is associated with angiogenesis and prognosis in malignant canine mammary tumors
10.1016/j.vetimm.2016.06.006 · 2016 · External reference
Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate
10.1016/j.vetimm.2020.110169 · 2021 · External reference
Expression of MAGE-A restricted to testis and ovary or to various cancers in dogs
10.1016/j.vetimm.2013.01.012 · 2013 · External reference
Comparison of tyrosinase-related protein-2, S-100, and Melan A immunoreactivity in canine amelanotic melanomas
10.1354/vp.40-6-713 · 2003 · External reference
Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function
10.1371/journal.pone.0235518 · 2020 · External reference
PD-1 expression by canine T cells and functional effects of PD-1 blockade
10.1111/vco.12294 · 2017 · External reference
Safety evaluation of autologous tissue vaccine cancer immunotherapy in a canine model
10.21873/anticanres.13275 · 2019 · External reference
A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients
10.1158/2326-6066.cir-18-0500 · 2019 · External reference
Development of effective tumor immunotherapy using a novel dendritic cell–targeting Toll-like receptor ligand
10.1371/journal.pone.0188738 · 2017 · External reference
Deregulation of VEGFR-2 and PDGFR expression and microvascular density in a triple-negative model of canine malignant mammary tumors with lymph node or lung metastasis
10.3390/vetsci6010003 · 2019 · External reference
Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
10.1016/j.tranon.2021.101205 · 2021 · External reference
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
2002 · External reference
Unresolved reference
External reference
M1 and M2 macrophages’ clinicopathological significance in cutaneous melanoma
10.1097/cmr.0000000000000352 · 2017 · External reference
The testis in immune privilege
10.1111/j.1600-065x.2006.00438.x · 2006 · External reference
Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up
10.1038/cgt.2012.72 · 2012 · External reference
Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma
10.1111/jvim.15852 · 2020 · External reference
Cancer registration in dogs and cats: A narrative review of history, current status, and standardization efforts
10.1016/j.rvsc.2025.105673 · 2025 · External reference
Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer
2017 · External reference
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
10.1084/jem.192.7.1027 · 2000 · External reference
Prognostic value of tumor-infiltrating lymphocytes in melanoma: A systematic review and meta-analysis
10.1080/2162402x.2019.1593806 · 2019 · External reference
de O. Association of systemic inflammatory and immune indices with survival in canine patients with oral melanoma, treated with experimental immunotherapy alone or experimental immunotherapy plus metronomic chemotherapy
10.3389/fvets.2022.888411 · 2022 · External reference
Role of tumor-infiltrating lymphocytes in melanoma prognosis and treatment strategies: A systematic review and meta-analysis
10.1016/j.heliyon.2024.e32433 · 2024 · External reference
Does TLS exist in canine mammary gland tumours? Preliminary results in simple carcinomas
10.3390/vetsci9110628 · 2022 · External reference
CD8+ T cells in the cancer-immunity cycle
10.1016/j.immuni.2023.09.005 · 2023 · External reference
Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas
10.1111/pcmr.12170 · 2014 · External reference
Prospective clinical trial of masitinib mesylate treatment for advanced stage III and IV canine malignant melanoma
10.1111/jsap.13111 · 2020 · External reference
Pilot acute safety evaluation of InnocellTM cancer immunotherapy in canine subjects
10.1155/2020/7142375 · 2020 · External reference
Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer
10.1371/journal.pone.0033274 · 2012 · External reference
Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours
10.1111/jsap.12480 · 2016 · External reference
Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor
10.2460/ajvr.72.12.1631 · 2011 · External reference
Immunohistochemical expression and prognostic significance of MAGE-A in canine oral malignant melanoma
10.1016/j.rvsc.2021.05.009 · 2021 · External reference
Hemangiosarcoma cells induce M2 polarization and PD-L1 expression in macrophages
10.1038/s41598-022-06203-w · 2022 · External reference
Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen
2005 · External reference
The hallmarks of cancer
10.1016/s0092-8674(00)81683-9 · 2000 · External reference
B cells and tertiary lymphoid structures promote immunotherapy response
10.1038/s41586-019-1922-8 · 2020 · External reference
Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis
10.1371/journal.pgen.1007589 · 2018 · External reference
Molecular targets for anticancer therapies in companion animals and humans: What can we learn from each other?
10.7150/thno.55760 · 2021 · External reference
Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma
10.1007/s00262-007-0353-9 · 2008 · External reference
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
10.1016/s1470-2045(18)30700-9 · 2018 · External reference
Relationship between regulatory and type 1 T cells in dogs with oral malignant melanoma
10.1111/j.1348-0421.2009.00194.x · 2010 · External reference
Characterization of myeloid-derived suppressor cells and cytokines GM-CSF, IL-10 and MCP-1 in dogs with malignant melanoma receiving a GD3-based immunotherapy
10.1016/j.vetimm.2019.109912 · 2019 · External reference
Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors
10.4142/jvs.23144 · 2024 · External reference
Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: A follow-up case report
10.1111/vco.12829 · 2022 · External reference
A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs
10.1038/s41598-020-75533-4 · 2020 · External reference
Density of tumor-infiltrating granzyme B-positive cells predicts favorable prognosis in dogs with transitional cell carcinoma
10.1016/j.vetimm.2017.07.001 · 2017 · External reference
Natural killer T and natural killer cell-based immunotherapy strategies targeting cancer
10.3390/biom13020348 · 2023 · External reference
Macrophage markers in serum and tumor have prognostic impact in American joint committee on cancer stage I/II melanoma
10.1200/jco.2008.19.9919 · 2009 · External reference
Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma
10.1007/s00262-007-0282-7 · 2007 · External reference
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
10.1056/nejmoa1001294 · 2010 · External reference
The use of melanosomal proteins in the immunotherapy of melanoma
10.1097/00002371-199807000-00001 · 1998 · External reference
Evaluation of SOX-10 immunohistochemical expression in canine melanoma and non-melanocytic tumors by tissue microarray
10.1177/03009858241273318 · 2024 · External reference
Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600 E/K mutated malignant melanomas
10.1038/s41598-021-81330-4 · 2021 · External reference
Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma
10.1038/s41417-019-0080-3 · 2019 · External reference
Tumor-infiltrating lymphocytes in cancer immunotherapy: From chemotactic recruitment to translational modeling
10.3389/fimmu.2025.1601773 · 2025 · External reference
Immunohistochemical evaluation of immune cell infiltration in canine gliomas
10.1177/03009858211023946 · 2021 · External reference
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: Results of a randomized phase II study of the European organisation for research and treatment of cancer melanoma group in metastatic melanoma
10.1200/jco.2012.43.7111 · 2013 · External reference
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
10.1084/jem.182.2.459 · 1995 · External reference
Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma
10.1007/s00262-018-2201-5 · 2018 · External reference
Prognostic impact of B-cell density in cutaneous melanoma
10.1007/s00262-011-1071-x · 2011 · External reference
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients
10.1080/2162402x.2018.1537581 · 2019 · External reference
CE. Expression and prognostic significance of vascular endothelial growth factor-A (VEGF-A) and its receptor in canine prostate cancer
10.1002/pros.24199 · 2021 · External reference
Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma
10.1007/s00262-021-03033-z · 2022 · External reference
Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models
10.1186/s12917-021-03026-1 · 2021 · External reference
Immune checkpoint inhibitors in melanoma: Mechanisms, immune cell interactions, and the tumour microenvironment
10.3389/fimmu.2025.1691608 · 2025 · External reference
Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma
2006 · External reference
PD-1 antibody monotherapy for malignant melanoma: A systematic review and meta-analysis
10.1371/journal.pone.0160485 · 2016 · External reference
KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates biologic activity against both normal and malignant canine mast cells
10.1158/1078-0432.ccr-16-2152 · 2017 · External reference
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies
2003 · External reference
Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision
10.1158/1078-0432.ccr-08-1860 · 2009 · External reference
Evaluation of an autologous cancer vaccine for the treatment of metastatic canine hemangiosarcoma: A preliminary study
10.1186/s12917-020-02675-y · 2020 · External reference
Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours
10.1371/journal.pone.0291727 · 2023 · External reference
Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade
10.1371/journal.pone.0098415 · 2014 · External reference
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
10.1038/s41698-021-00147-6 · 2021 · External reference
Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma
10.1371/journal.pone.0157176 · 2016 · External reference
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma
10.1038/s41598-017-09444-2 · 2017 · External reference
Determinants of BRAF mutations in primary melanomas
10.1093/jnci/djg123 · 2003 · External reference
Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs
10.1111/j.1939-1676.2010.0627.x · 2011 · External reference
Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients
10.1038/s41598-021-00325-3 · 2021 · External reference
Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: A 5-year experience in two veterinary oncology centers
10.1186/s40425-019-0624-y · 2019 · External reference
A target animal effectiveness study on adjuvant peptide-based vaccination in dogs with non-metastatic appendicular osteosarcoma undergoing amputation and chemotherapy
10.3390/cancers14051347 · 2022 · External reference
Sorafenib for the treatment of unresectable hepatocellular carcinoma: Preliminary toxicity and activity data in dogs
10.3390/cancers12051272 · 2020 · External reference
A phase 2, single-arm, open-label clinical trial on adjuvant peptide-based vaccination in dogs with aggressive hemangiosarcoma undergoing surgery and chemotherapy
10.3390/cancers15174209 · 2023 · External reference
Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
10.1080/19420862.2021.2004638 · 2021 · External reference
Immunotherapy with a HER2-targeting listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma
10.1158/1078-0432.ccr-16-0088 · 2016 · External reference
Chondroitin sulfate proteoglycan-4: A biomarker and a potential immunotherapeutic target for canine malignant melanoma
10.1016/j.tvjl.2011.02.020 · 2011 · External reference
Expression hierarchy of T cell epitopes from melanoma differentiation antigens: Unexpected high level presentation of tyrosinase-HLA-A2 complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies
10.4049/jimmunol.0801898 · 2009 · External reference
IFNγ markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models
10.1158/0008-5472.can-10-0600 · 2010 · External reference
Tumour-associated macrophages: Relation with progression and invasiveness, and assessment of M1/M2 macrophages in canine mammary tumours
10.1016/j.tvjl.2018.02.016 · 2018 · External reference
Burgeoning oncology pipeline raises questions about sustainability
10.1038/nrd.2018.165 · 2018 · External reference
Standardized approach for evaluating tumor infiltrating lymphocytes in canine mammary carcinoma: Spatial distribution and score as relevant features of tumor malignancy
10.1016/j.tvjl.2022.105833 · 2022 · External reference
Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector
10.1111/vco.12642 · 2021 · External reference
CD20+ B cells: The other tumor-infiltrating lymphocytes
10.4049/jimmunol.1001323 · 2010 · External reference
Cancer-testis antigens in canine histiocytic sarcoma and other malignancies
10.1111/vco.12475 · 2019 · External reference
Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1
10.1016/j.vetimm.2018.02.007 · 2018 · External reference
NK cell infiltration is associated with improved overall survival in solid cancers: A systematic review and meta-analysis
10.1016/j.tranon.2020.100930 · 2021 · External reference
Treatment combining CD200 immune checkpoint inhibitor and tumor-lysate vaccination after surgery for pet dogs with high-grade glioma
10.3390/cancers11020137 · 2019 · External reference
A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma
10.1111/vco.12057 · 2013 · External reference
Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma
10.1080/2162402x.2019.1676615 · 2020 · External reference
M1 and M2 tumour-associated macrophages subsets in canine malignant mammary tumours: An immunohistochemical study
10.1016/j.rvsc.2021.02.007 · 2021 · External reference
Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy
10.1158/1078-0432.ccr-22-1366 · 2023 · External reference
Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in patients with high-risk melanoma
10.1158/2326-6066.cir-19-0545 · 2020 · External reference
Oncolytic adenoviruses for the treatment of human cancer: Focus on translational and clinical data
10.1021/mp100219n · 2011 · External reference
Unresolved reference
External reference
Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination
10.1111/vco.12239 · 2017 · External reference
Melanoma antigens and related immunological markers
10.1016/j.critrevonc.2017.05.001 · 2017 · External reference
Melanoma of the dog and cat: Consensus and guidelines
2024 · External reference
FoxP3, CTLA-4, and IDO in canine melanocytic tumors
10.1177/0300985820960131 · 2021 · External reference
FoxP3 and IDO in canine melanocytic tumors
10.1177/0300985818808530 · 2019 · External reference
Tumour-associated macrophages in canine oral and cutaneous melanomas and melanocytomas: Phenotypic and prognostic assessment
10.3389/fvets.2022.878949 · 2022 · External reference
Tumour‐infiltrating lymphocytes in canine melanocytic tumours: An investigation on the prognostic role of CD3+ and CD20+ lymphocytic populations
10.1111/vco.12556 · 2020 · External reference
Tyrosine kinase inhibitors in cancer: Breakthrough and challenges of targeted therapy
10.3390/cancers12030731 · 2020 · External reference
Cytotoxic NK cells impede response to checkpoint immunotherapy in melanoma with an immune-excluded phenotype
10.1158/2159-8290.cd-24-1208 · 2025 · External reference
Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases
10.1354/vp.37-6-597 · 2000 · External reference
Immunohistochemical identification of canine melanocytic neoplasms with antibodies to melanocytic antigen PNL2 and tyrosinase: Comparison with melan A
10.1177/0300985810382095 · 2011 · External reference
Localization of integrin αvβ3 and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in cutaneous and oral melanomas of dog
2003 · External reference
Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer
10.1136/jitc-2023-007963 · 2024 · External reference
Comparative transcriptomic analysis of tumor-infiltrating canine natural killer cells and candidate biomarkers from first-in-dog NK immunotherapy trials
10.3389/fimmu.2025.1646849 · 2025 · External reference
CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA
10.1158/1078-0432.ccr-13-3042 · 2014 · External reference
Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: A veterinary trial
10.1136/jitc-2021-004007 · 2022 · External reference
Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma
10.1177/1758835919855491 · 2019 · External reference
APAVAC immunotherapy for the adjuvant treatment of a canine mucosal melanoma
10.3390/vetsci11120628 · 2024 · External reference
Mammary tumor development in dogs is associated with BRCA1 and BRCA2
10.1158/0008-5472.can-09-1725 · 2009 · External reference
Unedited allogeneic iNKT cells show extended persistence in MHC-mismatched canine recipients
2023 · External reference
Lymphoid aggregates in canine cutaneous and subcutaneous sarcomas: Immunohistochemical and gene expression evidence for tertiary lymphoid structures
10.1111/vco.13020 · 2025 · External reference
Association of tumour-infiltrating regulatory T cells with adverse outcomes in dogs with malignant tumours
10.1111/vco.12383 · 2018 · External reference
MAGE-A antigens as targets for cancer immunotherapy
10.1016/j.ctrv.2018.04.009 · 2018 · External reference
Cross-species genomics identifies DLG2 as a tumor suppressor in osteosarcoma
10.1038/s41388-018-0444-4 · 2019 · External reference
Immune checkpoint therapy-Current perspectives and future directions
10.1016/j.cell.2023.03.006 · 2023 · External reference
Programmed cell death ligand 1 expression in canine cancer
2016 · External reference
Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients
10.1158/1535-7163.mct-13-0288 · 2014 · External reference
Immunohistochemical diagnosis of canine oral amelanotic melanocytic neoplasms
10.1177/0300985810387447 · 2011 · External reference
Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53
10.1371/journal.pone.0056912 · 2013 · External reference
T cell immune profiles of blood and tumor in dogs diagnosed with malignant melanoma
10.3389/fvets.2021.772932 · 2021 · External reference
Prospective study of successful autologous dendritic cell therapy in dogs with splenic stage II hemangiosarcoma
10.1016/j.tvjl.2024.106196 · 2024 · External reference
Phase I pharmacologic and biologic study of ramucirumab (imc-1121b), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2
10.1200/jco.2009.23.7537 · 2010 · External reference
A preliminary study of the cross-reactivity of canine MAGE-A with hominid monoclonal antibody 6C1 in canine mammary gland tumors: An attractive target for cancer diagnostic, prognostic and immunotherapeutic development in dogs
10.3390/vetsci7030109 · 2020 · External reference
Long-term relative survival in uveal melanoma: A systematic review and meta-analysis
10.1038/s43856-022-00082-y · 2022 · External reference
Association between metastatic melanoma response to checkpoint inhibitor therapy and tumor-infiltrating lymphocyte classification on primary cutaneous melanoma biopsies
10.1001/jamadermatol.2022.4959 · 2023 · External reference
PD-1, PD-L1, and PD-L2 gene expression and tumor infiltrating lymphocytes in canine melanoma
10.1177/03009858211011939 · 2021 · External reference
Prognostic significance of primary tumor-infiltrating lymphocytes in a contemporary melanoma cohort
10.1245/s10434-022-11478-4 · 2022 · External reference
Immunohistochemical detection of melanoma-specific antigens in spontaneous canine melanoma
10.1053/jcpa.2002.0576 · 2002 · External reference
Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma
10.1371/journal.pone.0201222 · 2018 · External reference
Induction of dendritic cell-mediated immune responses against canine malignant melanoma cells
10.1016/j.tvjl.2006.11.005 · 2008 · External reference
A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: A case report and in vitro analysis
10.1186/s12917-021-02864-3 · 2021 · External reference
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma
10.1002/cncr.31734 · 2018 · External reference
A chimeric human/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma
10.1016/j.ymthe.2023.06.004 · 2023 · External reference
Receptor tyrosine kinases in osteosarcoma treatment: Which is the key target?
10.3389/fonc.2020.01642 · 2020 · External reference
A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma
10.1292/jvms.15-0510 · 2016 · External reference
Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial
10.1158/2326-6066.cir-13-0089 · 2013 · External reference
Unresolved reference
External reference
Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma
10.1111/j.1939-1676.2007.tb02936.x · 2007 · External reference
Tumor-induced myeloid deviation: When myeloid-derived suppressor cells meet tumor-associated macrophages
10.1172/jci80006 · 2015 · External reference
Unresolved reference
External reference
Comparative expression pathway analysis of human and canine mammary tumors
10.1186/1471-2164-10-135 · 2009 · External reference
Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK
10.1111/jsap.12613 · 2017 · External reference
Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors
10.1517/14728222.2015.1068759 · 2015 · External reference
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study
10.1016/s0140-6736(23)02268-7 · 2024 · External reference
Streptavidin: A novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines
10.1158/2326-6066.cir-13-0157 · 2014 · External reference
Preliminary study of plasma vascular endothelial growth factor (VEGF) during low- and high-dose radiation therapy of dogs with spontaneous tumors
10.1111/j.1740-8261.2004.04045.x · 2004 · External reference
Plasma vascular endothelial growth factor (VEGF) measured in seventy dogs with spontaneously occurring tumours
2004 · External reference
Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma
10.1097/cji.0b013e31829d8a1b · 2013 · External reference
Estimation of clinical trial success rates and related parameters
10.1093/biostatistics/kxx069 · 2019 · External reference
Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma
10.1158/1078-0432.ccr-18-2652 · 2019 · External reference
Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study
10.1111/vco.12332 · 2018 · External reference
The role of angiogenesis in melanoma: Clinical treatments and future expectations
10.3389/fphar.2022.1028647 · 2022 · External reference
Immunotherapeutic allogeneic dendritic cell and autologous tumor cell fusion vaccine alone or combined with radiotherapy in canine oral malignant melanoma is safe and potentially effective
10.3389/fvets.2024.1397518 · 2024 · External reference
Randomized phase II study of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma
10.1200/jco.20.00902 · 2021 · External reference
Genomic features of exceptional response in vemurafenib cobimetinib–treated patients with BRAFV600-mutated metastatic melanoma
10.1158/1078-0432.ccr-18-0720 · 2019 · External reference
Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs
10.1016/j.vetimm.2016.10.011 · 2016 · External reference
Intratumoral T-lymphocyte subsets in canine oral melanoma and their association with clinical and histopathological parameters
10.1177/0300985821999321 · 2021 · External reference
CD204+ tumor-associated macrophages are associated with clinical outcome in canine pulmonary adenocarcinoma and transitional cell carcinoma
10.1016/j.tvjl.2023.105992 · 2023 · External reference
Myeloid derived suppressor cells in peripheral blood can be a prognostic factor in canine transitional cell carcinoma
10.1016/j.vetimm.2024.110716 · 2024 · External reference
Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
10.1080/19420862.2023.2287250 · 2023 · External reference
Recent advances in therapeutic cancer vaccines
10.1038/s41568-025-00820-z · 2025 · External reference
Real-world efficacy and safety of anti-PD-1 antibody plus apatinib and temozolomide for advanced acral melanoma
10.2147/cmar.s520937 · 2025 · External reference
Neoantigen: A new breakthrough in tumor immunotherapy
2021 · External reference
Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma
10.1136/jitc-2023-008611 · 2024 · External reference
New insights into the role of macrophages in cancer immunotherapy
2024 · External reference
